PDLIM7 and nasopharyngeal carcinoma: The adoption of cytotoxic T cells specific to EBV as a complement to standard treatment to prevent and effectively treat NPC cells positive for EBV expressing subdominant EBV antigens (EBNA1, LMP1/2) has been proposed [37] and, therefore, they could be identified, activated, and multiplied for immunotherapeutic purposes.